The Hunter Williams Podcast Dihexa Deep Dive | Dosing, Safety, and Why I Keep Coming Back to It
Mar 24, 2026
A deep dive into a synthetic nootropic and its origins, including how it acts on HGF/c-Met to drive synaptogenesis. A look at the scandalous research history and a failed pro-drug attempt. Reviews of animal and limited human data, long half-life implications, dosing methods, cycling recommendations, and safety concerns around cancer pathways.
AI Snips
Chapters
Transcript
Episode notes
Personal Preference For Middle Ground Nootropic
- Hunter prefers milder nootropics that preserve personality; Dihexa hits a middle ground — noticeable but not personality-erasing.
- He contrasts it with strong stimulants (Modafinil/Adderall) he avoids because they can make him feel robotic or reduce empathy.
How Dihexa Rewires The Brain
- Dihexa is a synthetic peptide that promotes synaptogenesis by binding HGF and activating c-MET, triggering PI3K/AKT → MAPK/ERK signaling.
- In vitro it induced synapse formation at picomolar concentrations, far more potent than BDNF by molar comparison.
Research Scandal Shaped Dihexa's Clinical Path
- The Dihexa development story includes corporate scandal: researchers co-founded M3/Athera, raised >$200M, then faced paper retractions and a CEO PhD revocation, costing $14M in settlements.
- This affected clinical translation: the patented pro-drug ATH-1017 failed to deliver Dihexa's effects and trials did not meet endpoints.